Total Payments
$836.26
2024 Payments
$121.80
Companies
10
Transactions
16
Medicare Patients
3,705
Medicare Billing
$731,776
Payment Breakdown by Category
Food & Beverage$750.03 (89.7%)
Education$86.23 (10.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $750.03 | 14 | 89.7% |
| Education | $86.23 | 2 | 10.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $255.53 | 4 | $0 (2023) |
| BIOTRONIK INC. | $139.63 | 1 | $0 (2022) |
| La Jolla Pharmaceutical Company | $121.80 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $106.43 | 1 | $0 (2017) |
| Astellas Pharma US Inc | $85.12 | 2 | $0 (2018) |
| Allergan Inc. | $31.58 | 2 | $0 (2018) |
| AbbVie, Inc. | $31.43 | 2 | $0 (2018) |
| ViiV Healthcare Company | $24.48 | 1 | $0 (2023) |
| GENZYME CORPORATION | $24.02 | 1 | $0 (2019) |
| Insmed, Inc. | $16.24 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121.80 | 1 | La Jolla Pharmaceutical Company ($121.80) |
| 2023 | $46.99 | 2 | ViiV Healthcare Company ($24.48) |
| 2022 | $155.87 | 2 | BIOTRONIK INC. ($139.63) |
| 2019 | $24.02 | 1 | GENZYME CORPORATION ($24.02) |
| 2018 | $133.66 | 5 | Astellas Pharma US Inc ($85.12) |
| 2017 | $353.92 | 5 | Gilead Sciences Inc ($233.02) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $121.80 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/10/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.51 | General |
| 05/05/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: HIV | ||||||
| 07/14/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 03/28/2022 | BIOTRONIK INC. | BIOMONITOR (Device), Edora 8 DR-T, Acticor 7 VR-T DX | Food and Beverage | In-kind items and services | $139.63 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/21/2019 | GENZYME CORPORATION | LIBTAYO (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2018 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: Virology | ||||||
| 04/30/2018 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Virology | ||||||
| 03/07/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/25/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $69.99 | General |
| 01/25/2018 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 12/13/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/01/2017 | Merck Sharp & Dohme Corporation | ZINPLAVA (Biological) | Food and Beverage | In-kind items and services | $106.43 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/09/2017 | Gilead Sciences Inc | Epclusa (Drug) | Food and Beverage | In-kind items and services | $111.86 | General |
| Category: HCV | ||||||
| 03/15/2017 | Gilead Sciences Inc | Genvoya (Drug) | Food and Beverage | In-kind items and services | $116.06 | General |
| Category: HIV | ||||||
| 02/17/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $5.10 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 682 | 1,189 | $487,968 | $136,898 |
| 2022 | 10 | 1,014 | 1,679 | $708,579 | $189,971 |
| 2021 | 11 | 974 | 1,713 | $671,901 | $189,460 |
| 2020 | 8 | 1,035 | 2,014 | $752,004 | $215,447 |
Total Patients
3,705
Total Services
6,595
Medicare Billing
$731,776
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 297 | 704 | $240,768 | $75,827 | 31.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 199 | 214 | $141,882 | $33,603 | 23.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 115 | 179 | $42,423 | $12,827 | 30.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 45 | $28,575 | $6,874 | 24.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 13 | 17 | $16,490 | $3,191 | 19.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $10,010 | $2,610 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 17 | $7,820 | $1,965 | 25.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 369 | 831 | $284,236 | $76,541 | 26.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 272 | 285 | $188,955 | $50,742 | 26.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 189 | 326 | $77,145 | $20,881 | 27.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 27 | 56 | $54,320 | $10,808 | 19.9% |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | Office | 2022 | 23 | 23 | $20,700 | $10,426 | 50.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 34 | 46 | $29,210 | $6,910 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 27 | 39 | $17,940 | $4,658 | 26.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 48 | 48 | $19,056 | $4,311 | 22.6% |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | Office | 2022 | 12 | 12 | $7,007 | $2,373 | 33.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $10,010 | $2,322 | 23.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 350 | 739 | $252,626 | $69,216 | 27.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 257 | 268 | $177,684 | $48,471 | 27.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 173 | 297 | $70,218 | $19,355 | 27.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 53 | 95 | $42,556 | $11,501 | 27.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 15 | 140 | $31,500 | $10,776 | 34.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 51 | $31,695 | $8,147 | 25.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 21 | 40 | $26,260 | $7,846 | 29.9% |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | Office | 2021 | 11 | 11 | $9,900 | $6,500 | 65.7% |
About Dr. Konark Sharma, M.D
Dr. Konark Sharma, M.D is a Infectious Disease healthcare provider based in Walnut Creek, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114975562.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Konark Sharma, M.D has received a total of $836.26 in payments from pharmaceutical and medical device companies, with $121.80 received in 2024. These payments were reported across 16 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($750.03).
As a Medicare-enrolled provider, Sharma has provided services to 3,705 Medicare beneficiaries, totaling 6,595 services with total Medicare billing of $731,776. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Walnut Creek, CA
- Active Since 05/05/2006
- Last Updated 03/18/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1114975562
Products in Payments
- BIOMONITOR (Device) $139.63
- XERAVA (Drug) $121.80
- Genvoya (Drug) $116.06
- Epclusa (Drug) $111.86
- ZINPLAVA (Biological) $106.43
- DALVANCE (Drug) $31.58
- Mavyret (Drug) $31.43
- CABENUVA (Biological) $24.48
- LIBTAYO (Drug) $24.02
- Arikayce (Drug) $16.24
- CRESEMBA (Drug) $15.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Walnut Creek
Dr. Ronald Wasserman, M.d, M.D
Infectious Disease — Payments: $3,199
Infectious Disease $3,199
Dr. Jorge Bernett, M.d, M.D
Infectious Disease — Payments: $2,163
Infectious Disease $2,163
Dr. Joshua Perlroth, M.d, M.D
Infectious Disease — Payments: $1,104
Infectious Disease $1,104
Jennifer Cheng, D.o, D.O
Infectious Disease — Payments: $940.94
Infectious Disease $940.94
Nimisha Mishra-Shukla, Md, MD
Infectious Disease — Payments: $705.50
Infectious Disease $705.50
Dr. Bela Chheda, M.d, M.D
Infectious Disease — Payments: $308.18
Infectious Disease $308.18